Clinical Trials Browser

Interventional × Adenocarcinoma × Ramucirumab × Clear all

NCT04704934 2026-01-12

Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)

Phase 3 Active not recruiting

490 enrolled

Gastrointestinal

Adenocarcinoma, Stomach Neoplasms

NCT05980416 2025-11-14

Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2

Phase 1 Terminated

88 enrolled 18 charts

Gastrointestinal

Adenocarcinoma, Digestive System Neoplasms, Gastrointestinal Neoplasms, Neoplasms, Neoplasms by Site, Stomach Neoplasms

NCT04069273 2025-07-31

SEQUEL

Phase 2 Recruiting

58 enrolled

Gastrointestinal

Adenocarcinoma, Stomach Neoplasms

NCT03995017 2023-02-01

RiME

Phase 1/2 Unknown

34 enrolled

Gastrointestinal

Adenocarcinoma Of Esophagus, Adenocarcinoma, Stomach Neoplasms

NCT02213289 2021-04-08

PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression

Phase 2 Completed

80 enrolled 14 charts

Tumor-Agnostic

Adenocarcinoma

NCT00917384 2019-09-25

Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma

Phase 3 Completed

355 enrolled 16 charts

Gastrointestinal

Adenocarcinoma, Neoplasm Metastasis, Stomach Neoplasms

NCT01170663 2019-09-18

RAINBOW

Phase 3 Completed

665 enrolled 24 charts

Gastrointestinal

Adenocarcinoma, Stomach Neoplasms

NCT01111604 2019-08-06

A Study of Ramucirumab or Icrucumab in Colorectal Cancer

Phase 2 Completed

158 enrolled 17 charts

Gastrointestinal

Adenocarcinoma, Colonic Neoplasms, Rectal Neoplasms

NCT01253525 2014-06-18

Study of Weekly Paclitaxel With Ramucirumab in Participants With Advanced Gastric Adenocarcinomas

Phase 1 Completed

6 enrolled 18 charts

Tumor-Agnostic

Adenocarcinoma